Scarica l'app Stockscreener
90.73
1.10%
0.99
Dopo l'orario di chiusura:
91.00
0.27
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Franklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Barclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Sleep Apnea Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma - Barchart
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 4%Here's What Happened - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lowered by State Street Corp - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 7.9% in November - MarketBeat
Axsome Therapeutics' SWOT analysis: strong growth, pipeline potential lift stock - Investing.com
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? - MSN
Captrust Financial Advisors Acquires Shares of 5,722 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wellington Management Group LLP Acquires 8,125 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Fmr LLC Has $97.79 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Charles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is RTW Investments LP's 2nd Largest Position - MarketBeat
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HighVista Strategies LLC Sells 20,650 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market - The Globe and Mail
Smoking Cessation and Nicotine Addiction Market Growth - openPR
PDT Partners LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
9,466 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fred Alger Management LLC - MarketBeat
Trend Tracker for (AXSM) - Stock Traders Daily
Bellevue Group AG Decreases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Eventide Asset Management LLC Has $74.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: Focus On AXS-12 Targeting Narcolepsy, Just Released Positive Data (NASDAQ:AXSM) - Seeking Alpha
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Cynosure Group LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - AOL
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
HC Wainwright Has Bullish Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome's AXS-12 shows efficacy in narcolepsy trial By Investing.com - Investing.com Canada
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy - MSN
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Positive Phase III data in narcolepsy from Axsome - The Pharma Letter
Axsome Therapeutics Announces AXS-12 Achieves Primary - GlobeNewswire
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week - Yahoo Finance
Axsome's AXS-12 shows efficacy in narcolepsy trial - Investing.com India
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy - The Manila Times
Loomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome's AXS-12 Shows 77% Reduction in Narcolepsy Attacks in Phase 3 Trial Success | AXSM Stock News - StockTitan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome shares reiterate Buy rating on strong Q3 results By Investing.com - Investing.com UK
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet? - Simply Wall St
Eagle Asset Management Inc. Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Landscape Capital Management L.L.C. Makes New $585,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Invests $830,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 - openPR
Excessive Daytime Sleepiness Market to Witness Growth During the Forecast Period | Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio - The Globe and Mail
(AXSM) Long Term Investment Analysis - Stock Traders Daily
Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):